Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 17915

1.

Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.

Enriquez A, Lip GY, Baranchuk A.

Europace. 2015 Mar 26. pii: euv030. [Epub ahead of print] Review.

PMID:
25816811
2.

Simultaneous thrombosis of the left anterior descending artery and the right coronary artery in a 34-year-old crystal methamphetamine abuser.

Khaheshi I, Mahjoob MP, Esmaeeli S, Eslami V, Haybar H.

Korean Circ J. 2015 Mar;45(2):158-60. doi: 10.4070/kcj.2015.45.2.158. Epub 2015 Mar 24.

3.

Antithrombotic treatment at onset of stroke with atrial fibrillation, functional outcome, and fatality: a systematic review and meta-analysis.

Hannon N, Arsava EM, Audebert HJ, Ay H, Crowe M, Ní Chróinín D, Furie K, McGorrian C, Molshatzki N, Murphy S, Noone I, O'Donnell M, Schenkel J, Tan KM, Tanne D, Kelly PJ.

Int J Stroke. 2015 Mar 22. doi: 10.1111/ijs.12473. [Epub ahead of print]

PMID:
25808552
4.

Novel anticoagulants and antiplatelet agents; a guide for the urologist.

Ellis G, Camm AJ, Datta SN.

BJU Int. 2015 Mar 23. doi: 10.1111/bju.13131. [Epub ahead of print]

PMID:
25808010
5.

Novel oral anticoagulants in atrial fibrillation: which novel oral anticoagulant for which patient?

Prisco D, Cenci C, Silvestri E, Ciucciarelli L, Di Minno G.

J Cardiovasc Med (Hagerstown). 2015 Mar 19. [Epub ahead of print]

PMID:
25798903
6.

Overview of the New Oral Anticoagulants: Opportunities and Challenges.

Yeh CH, Hogg K, Weitz JI.

Arterioscler Thromb Vasc Biol. 2015 Mar 19. pii: ATVBAHA.115.303397. [Epub ahead of print]

PMID:
25792448
7.

Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.

Laliberté F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P.

Adv Ther. 2015 Mar;32(3):216-27. doi: 10.1007/s12325-015-0189-1. Epub 2015 Mar 18.

PMID:
25784509
8.

Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs.

Verheugt FW, Granger CB.

Lancet. 2015 Mar 11. pii: S0140-6736(15)60245-8. doi: 10.1016/S0140-6736(15)60245-8. [Epub ahead of print] Review.

PMID:
25777666
9.

Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments.

Mega JL, Simon T.

Lancet. 2015 Mar 11. pii: S0140-6736(15)60243-4. doi: 10.1016/S0140-6736(15)60243-4. [Epub ahead of print] Review.

PMID:
25777662
10.

Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.

Cope S, Clemens A, Hammès F, Noack H, Jansen JP.

Value Health. 2015 Mar;18(2):234-49. doi: 10.1016/j.jval.2014.10.012. Epub 2015 Jan 28.

PMID:
25773559
11.

Engaging with quality improvement in anticoagulation management.

Barnes GD, Kline-Rogers E.

J Thromb Thrombolysis. 2015 Apr;39(3):403-9. doi: 10.1007/s11239-015-1184-8.

PMID:
25772116
12.

Patients With Atrial Fibrillation and a CHA2DS2-VASc Score of 1: Are They at Low or High Stroke Risk?

Huisman MV.

J Am Coll Cardiol. 2015 Mar 5. pii: S0735-1097(15)00435-0. doi: 10.1016/j.jacc.2015.02.010. [Epub ahead of print] No abstract available.

PMID:
25770316
13.

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM.

Lancet. 2015 Mar 10. pii: S0140-6736(14)61943-7. doi: 10.1016/S0140-6736(14)61943-7. [Epub ahead of print]

PMID:
25769361
14.

Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study.

Xiang W, Zhang J, Liu M, Liu F, Feng X, Wang Y.

Clin Interv Aging. 2015 Mar 2;10:515-9. doi: 10.2147/CIA.S67974. eCollection 2015.

15.

Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty.

Messerschmidt C, Friedman RJ.

Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):771-8. doi: 10.1161/ATVBAHA.114.303400. Epub 2015 Mar 12.

PMID:
25767271
16.

Treatment of venous thromboembolism in the era of non-vitamin K antagonist oral anticoagulants.

Uaprasert N.

J Med Assoc Thai. 2015 Jan;98 Suppl 1:S111-7.

PMID:
25764622
17.

Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial.

Farag M, Gorog DA.

Future Cardiol. 2015 Mar;11(2):147-51. doi: 10.2217/fca.15.4.

PMID:
25760874
18.

Left atrial appendage closure for atrial fibrillation--reply.

Reddy VY, Holmes D.

JAMA. 2015 Mar 10;313(10):1057-8. doi: 10.1001/jama.2015.0685. No abstract available.

PMID:
25756446
19.

Left atrial appendage closure for atrial fibrillation.

Stöllberger C, Schneider B.

JAMA. 2015 Mar 10;313(10):1057. doi: 10.1001/jama.2015.0682. No abstract available.

PMID:
25756445
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk